Browse by author
Lookup NU author(s): Dr Christopher Wright,
Dr Andrew Hall
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Sixty-eight patients with advanced breast cancer were treated with mitoxantrone and clinical responses assessed. Expression of c-erbB-2 protein and cytosolic glutathione S-transferase (GST) isoenzymes pi, alpha and mu by the primary tumours of these patients was determined immunohistochemically, and correlated with treatment response. Tumours overexpressing c-erbB-2 (n = 16, 23%) showed a lower response rate (50% vs 58%) and shorter duration of response to treatment, compared with c-erbB-2 negative tumours. These assciations were not statistically significant but survival following start of treatment was significantly shorter in the c-erbB-2 positive group. For each GST isoenzyme, the response rate and duration of response of the group showing enzyme expression did not differ significantly from those with negatively staining tumours. These data do not support a role for expression of GSTs alone in resistance to mitoxantrone monotherapy in advanced breast cancer. The poorer post treatment survival of patients with c-erbB-2 positive tumours suggests they could be selected for more intensive treatment regimens.
Author(s): Wright C, Cairns J, Cantwell BJ, Cattan AR, Hall AG, Harris AL, Horne CHW
Publication type: Article
Publication status: Published
Journal: British Journal of Cancer
Print publication date: 01/02/1992
ISSN (print): 0007-0920
ISSN (electronic): 1532-1827
PubMed id: 1346748